Literature DB >> 8591942

Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin.

M H Wilcox1, R Howe.   

Abstract

One hundred patients, known to have been excreting Clostridium difficile cytotoxin in faeces, were reviewed retrospectively to determine the response time for treatment with oral metronidazole and vancomycin, and the effect of the additional administration of anti-motility agents. Records were available for 78 patients of whom 58 had received treatment with either metronidazole or vancomycin. Response and relapse rates were similar for the two treatment regimens. However, the mean duration of symptoms was significantly shorter in evaluable patients treated with vancomycin (3.0 days, n = 22) compared with those given metronidazole (4.6 days, n = 28) (Mann-Whitney-U, P < 0.01). No difference in the duration of symptoms, irrespective of antibiotic therapy, was associated with use of anti-motility agents. The increased cost of vancomycin compared with metronidazole for the treatment of C. difficile infection may be justifiable by reductions in the length of stay in hospital or in the need for nursing in isolation facilities, consequent upon a shorter symptomatic response time. Administration of anti-motility agents did not appear to impair response in patients with mild to moderate C. difficile infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8591942     DOI: 10.1093/jac/36.4.673

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 2.  Management of infectious diarrhoea.

Authors:  A C Casburn-Jones; M J G Farthing
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

3.  Diarrhoea developing in hospital patients.

Authors:  R M McLoughlin; H J O'Connor
Journal:  Ir J Med Sci       Date:  2005 Jan-Mar       Impact factor: 1.568

4.  Clostridium difficile: The evolving story.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-11       Impact factor: 2.471

5.  [1997 gastroenterology update--I].

Authors:  W Fischbach; S S Gro; J Schölmerich; C Ell; P Layer; W E Fleig; H Zirngibl
Journal:  Med Klin (Munich)       Date:  1998-02-15

6.  Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications.

Authors:  Ramsey M Dallal; Brian G Harbrecht; Arthur J Boujoukas; Carl A Sirio; Linda M Farkas; Kenneth K Lee; Richard L Simmons
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

7.  Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.

Authors:  F Barbut; D Decré; B Burghoffer; D Lesage; F Delisle; V Lalande; M Delmée; V Avesani; N Sano; C Coudert; J C Petit
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

8.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 9.  The role of surgery in pseudomembranous enterocolitis.

Authors:  Y K Viswanath; C D Griffiths
Journal:  Postgrad Med J       Date:  1998-04       Impact factor: 2.401

Review 10.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.